Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000431950 | SCV000520841 | likely pathogenic | not provided | 2023-11-06 | criteria provided, single submitter | clinical testing | Reported as an unclassified variant in a patient who did not have a second variant in POLG and in multiple patients with second variants found to have ataxia and other features (PMID: 25118206, 29474836, 32600829); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 32347949, 24508722, 32600829, 21880868, 29474836, 25118206, 32382377) |
Labcorp Genetics |
RCV000693072 | SCV000820926 | uncertain significance | Progressive sclerosing poliodystrophy | 2024-01-10 | criteria provided, single submitter | clinical testing | This sequence change replaces phenylalanine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 88 of the POLG protein (p.Phe88Leu). This variant is present in population databases (rs144439703, gnomAD 0.02%). This missense change has been observed in individual(s) with clinical features of POLG-related conditions (PMID: 21880868, 25118206, 29474836, 32600829). ClinVar contains an entry for this variant (Variation ID: 381522). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt POLG protein function with a positive predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Wong Mito Lab, |
RCV000693072 | SCV000887296 | uncertain significance | Progressive sclerosing poliodystrophy | 2018-10-01 | criteria provided, single submitter | clinical testing | The NM_002693.2:c.264C>G (NP_002684.1:p.Phe88Leu) [GRCH38: NC_000015.10:g.89333491G>C] variant in POLG gene is interpretated to be a Uncertain Significance based on ACMG guidelines (PMID: 25741868). This variant meets the following evidence codes reported in the ACMG-guideline. PP3:Computational evidence/predictors indicate the variant has deleterious effect on POLG structure, function, or protein-protein interaction. Based on the evidence criteria codes applied, the variant is suggested to be Uncertain Significance. |
Baylor Genetics | RCV000693072 | SCV004205862 | pathogenic | Progressive sclerosing poliodystrophy | 2024-01-04 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004701468 | SCV005204940 | likely pathogenic | POLG-Related Spectrum Disorders | 2024-06-26 | criteria provided, single submitter | clinical testing | Variant summary: POLG c.264C>G (p.Phe88Leu) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.8e-05 in 248876 control chromosomes. c.264C>G has been reported in the literature in compound heterozygous or homozygous individuals affected with POLG-Related Spectrum Disorders (Shinagawa_2020, Masingue_2019, Parada-Garza_2020, Tang_2011). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 29474836, 32600829, 32382377, 21880868, 25118206). ClinVar contains an entry for this variant (Variation ID: 381522). Based on the evidence outlined above, the variant was classified as likely pathogenic. |
Mayo Clinic Laboratories, |
RCV000431950 | SCV000802097 | uncertain significance | not provided | 2017-11-01 | no assertion criteria provided | clinical testing |